Russian company Pharmsynthez and Lipoxen signed a collaboration centered on applying the latter’s PolyXen® protein delivery technology and ImuXen® vaccine delivery technology to a range of Pharmsynthez' drug and vaccine candidates. Lipoxen will provide scientific expertise for candidate optimization, and Pharmsynthez will fund and carry out clinical proof-of-concept trials in Russia.
Lipoxen’s ImuXen platform comprises a group of liposomal technologies designed to improve the delivery and effectiveness of DNA, protein, and polysaccharide vaccines. Pharmsynthez will use the technology with vaccine candidates for secondary progressive multiple sclerosis, HIV, and non-Hodgkin’s lymphoma.
PolyXen is an enabling technology that uses biopolymer polysialic acid to prolong the active life and improve the pharmacokinetics of therapeutic peptides, proteins, and small molecules. This platform will be used by Pharmsynthez in the development of drugs for the treatment of cystic fibrosis, acute myeloid leukaemia, non-Hodgkin’s lymphoma, and type 2 diabetes.
Related IP will be owned jointly by the two companies, unless it solely covers Lipoxen's platform technologies. Lipoxen will have the right to use all relevant clinical trial data to progress product development in other countries including the U.S. and those in Europe. The company will also earn 10% royalites on Pharmsynthez’ sale of relevant products in the Russian Federation.